×
DBV Technologies S.A EBIT Margin 2015-2025 | DBVT
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
DBV Technologies S.A ebit margin from 2015 to 2025. Ebit margin can be defined as earnings before interest and taxes as a portion of total revenues
View More
DBV Technologies S.A EBIT Margin 2015-2025 | DBVT
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
DBV Technologies S.A ebit margin from 2015 to 2025. Ebit margin can be defined as earnings before interest and taxes as a portion of total revenues
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$243.4B
Amgen (AMGN)
$156.3B
Gilead Sciences (GILD)
$147.7B
Vertex Pharmaceuticals (VRTX)
$100.1B
Bristol Myers Squibb (BMY)
$97.3B
CSL (CSLLY)
$85B
GSK (GSK)
$80B
Regeneron Pharmaceuticals (REGN)
$60B
Alnylam Pharmaceuticals (ALNY)
$58B
Argenex SE (ARGX)
$39.9B
BioNTech SE (BNTX)
$27.1B
Insmed (INSM)
$27B
Royalty Pharma (RPRX)
$20.5B
Biogen (BIIB)
$19.8B
Incyte (INCY)
$16.8B
Illumina (ILMN)
$15.4B
Genmab (GMAB)
$14.7B
Genmab (GNMSF)
$14.3B
Ascendis Pharma (ASND)
$11.7B
BioMarin Pharmaceutical (BMRN)
$11.1B
QIAGEN (QGEN)
$10.9B
Moderna (MRNA)
$10.4B
Exelixis (EXEL)
$10.4B
Swedish Orphan Biovitrum (BIOVF)
$10.3B
Verona Pharma American Depositary Share (VRNA)
$9B
Exact Sciences (EXAS)
$8.5B
Bio-Techne Corp (TECH)
$8.4B
Blueprint Medicines (BPMC)
$8.3B
Roivant Sciences (ROIV)
$8B
Halozyme Therapeutics (HALO)
$7.7B